Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Frequently asked questions
What sector does Minerva Neurosciences Inc (NERV) operate in?
Minerva Neurosciences Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Minerva Neurosciences Inc (NERV) current stock price?
As of the latest data, Minerva Neurosciences Inc stock price is $2.24, with a previous close of $2.20. Minerva Neurosciences Inc gained $0.04 in the last trading session, representing a 1.82% increase.
What is Minerva Neurosciences Inc (NERV) current market capitalization?
Minerva Neurosciences Inc market cap is approximately 106.95 million.
What is Minerva Neurosciences Inc (NERV) Earnings Per Share (EPS)?
The trailing EPS is -$34.41, and the forward EPS is -$0.42.
What is Minerva Neurosciences Inc (NERV) EBITDA?
Minerva Neurosciences Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 17.47 million.
Does Minerva Neurosciences Inc (NERV) pay dividends?
No. Minerva Neurosciences Inc does not pay a dividend.
When is Minerva Neurosciences Inc (NERV) next earnings report?
Minerva Neurosciences Inc is expected to release its next earnings report on September 30, 2026.
What is Minerva Neurosciences Inc (NERV) beta (volatility) score?
Minerva Neurosciences Inc has a beta of -0.098, indicating lower volatility than the overall market.
